Wells Fargo analyst David Maris says Bausch Health Companies' Q1 results demonstrate why the company reminds him a lot of the old Valeant and its price and deal driven model. The analyst adds that while some point to better than expected EBITDA, he sees low growth and high debt. Further, how price and deals contributed to Bausch's growth in Q1 is a reminder that "the more things have changed, the more they stay the same," Maris tells investors in a research note. In the press release, Bausch led with how Xifaxan grew 11%, but overall revenue growth of just 1% is not mentioned until the bottom of the press release, Maris points out. He keeps an Underperform rating on Bausch Health shares with a $9 price target.